Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
36 studies found for:    " January 07, 2009":" February 06, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
21 Unknown  Alveolar Macrophage Proteomics in HIV-associated Emphysema
Conditions: HIV;   Emphysema;   HIV Infections
Intervention:
22 Completed Early Versus Delayed Antiretroviral Therapy (ART) in the Treatment of Cryptococcal Meningitis in Africa
Conditions: Cryptococcal Meningitis;   HIV Infections
Interventions: Drug: Fluconazole;   Drug: Fixed dose - Stavudine, lamivudine and Nevirapine;   Drug: Fixed dose - Stavudine, Lamivudine, Nevirapine
23 Completed Renal Function Assessment in HIV Patient
Conditions: Chronic Kidney Disease;   HIV Infections
Intervention: Other: DEXA scan
24 Completed Acupuncture/Moxibustion (Acu/Moxa) for Distal Symmetric Peripheral Neuropathy (DSP) in HIV
Conditions: Peripheral Neuropathy;   HIV;   AIDS;   HIV Infections
Interventions: Other: Acupuncture / Moxibustion;   Other: Acupuncture/Moxibustion
25 Completed
Has Results
A Study Of Different Doses Of UK-453, 061 Plus Truvada Compared To Efavirenz Plus Truvada In Patients Who Have Not Been Previously Treated For HIV-1
Condition: HIV-1
Interventions: Drug: UK-453, 061;   Drug: EFV +TVA
26 Completed
Has Results
A Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive Human Immunodeficiency Virus - Type 1 (HIV-1) Infected Patients
Condition: Human Immunodeficiency Virus Type 1
Interventions: Drug: TMC310911 75 mg twice daily;   Drug: TMC310911 150 mg twice daily;   Drug: TMC310911 300 mg twice daily;   Drug: TMC310911 300 mg once daily;   Drug: Ritonavir 100 mg twice daily;   Drug: Ritonavir 100 mg once daily
27 Terminated
Has Results
A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1
Condition: HIV-1
Interventions: Drug: UK-453,061 Dose 1;   Drug: UK-453,061 Dose 2;   Drug: Etravirine
28 Terminated
Has Results
A Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1
Condition: HIV-1
Intervention: Drug: No drug will be administered
29 Completed TMC125-TiDP2-C188: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Effect of Multiple-dose TMC125 on Buprenorphine and Norbuprenorphine Administered in HIV-negative Patients on Stable Buprenorphine/Naloxone Maintenance Therapy.
Conditions: HIV;   Pharmacokinetics
Intervention: Drug: TMC125
30 Completed TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy Volunteer
Conditions: Tuberculosis;   HIV
Intervention: Drug: TMC207
31 Completed PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir
Condition: HIV-1
Intervention: Drug: TMC558445; TMC310911; Darunavir; Placebo
32 Completed Innovation-TiFP4-C101: A Study to Evaluate the Pharmacokinetics of TMC114 and TMC41629 After a Single Oral Dose of 2 Controlled-release Coformulations as Compared to an Immediate-release Coformulation of TMC114/TMC41629
Condition: HIV-I
Intervention: Drug: TMC114; TMC41629
33 Completed
Has Results
Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults
Condition: HIV-1 Infections
Interventions: Drug: Raltegravir;   Drug: Darunavir/Ritonavir
34 Completed
Has Results
Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.
Condition: Infections, Streptococcal
Interventions: Biological: Pneumococcal vaccine GSK1024850A;   Biological: Tritanrix-HepB/Hib;   Biological: measles;   Biological: Rotarix;   Biological: Local OPV
35 Completed VX-950-TiDP24-C134: Drug-drug Interaction Trial Between Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir on Healthy Volunteer
Conditions: Hepatitis C;   HCV;   HIV;   AIDS
Intervention: Drug: Efavirenz; Tenofovir disoproxil fumarate; Telaprevir
36 Active, not recruiting S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
Conditions: Lymphoma;   Nonneoplastic Condition
Interventions: Biological: bleomycin sulfate;   Biological: filgrastim;   Drug: ABVD regimen;   Drug: BEACOPP regimen;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vinblastine sulfate;   Drug: vincristine sulfate

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-36) Next Page   
Study has passed its completion date and status has not been verified in more than two years.